Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) Surges Over 7% in Morning Trade, Turnover at Approximately HKD 4.2304 Million
NewTimeSpace News: According to the latest data from the Hong Kong Stock Exchange, as of 11:10 on June 15, Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) jumped 7.06%, with the latest price at HKD 12.590. The ETF opened today at HKD 12.170, recording a high of HKD 12.650 and a low of HKD 11.980, representing an intraday swing of 5.70%. The ETF saw 540,000 shares traded, a turnover of approximately HKD 6.6989 million, an average price of HKD 12.405, a turnover rate of 3.72%, total Assets Under Management (AUM) of approximately HKD 171 million, a latest Net Asset Value (NAV) of HKD 11.760, and a discount rate of 1.21%.
Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) tracks the ChiNext Index. Launched by the Shenzhen Stock Exchange in 2010, the index is a constituent benchmark comprising the 100 most representative stocks with the largest market capitalization and highest liquidity in the ChiNext market. The index focuses on strategic emerging industries and high-tech enterprises, with significant coverage of high-growth sectors such as New Energy (e.g., power battery leaders), Biopharmaceuticals, Information Technology, and Advanced Manufacturing.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Sige New Energy (06656.HK): Change of Board Secretary and Joint Company Secretary, Exemption from Compliance Requirements Granted by HKEX
- ZTHC (00994.HK): Completes Placing of 150 Million New Shares with Net Proceeds of Approximately HK$53 Million
- Henlius(02696.HK): HLX3902 Injection (STEAP1xCD3xCD28 Trispecific Antibody) Gets NMPA Approval for Phase I Clinical Trial in Metastatic Castration-Resistant Prostate Cancer
- CNBM(03323.HK) closed 24.95% higher on Jun 17, leading the Hang Seng Construction Sector
- ITC PROPERTIES(00199.HK) closed 7.32% higher on Jun 17, the Hang Seng Properties Sector saw divergent trends